🧵 NEW PAPER in @BloodJournal!
Why do IDH1 mutations almost exclusively drive myeloid #leukemia, while IDH2 mutations occur in both myeloid AND lymphoid cancers? #AML#Epigenetics
Despite sharing the same biochemical mechanism, they are NOT equivalent. Here's what we found 👇
Decades of research have revealed the intricacies of how dendritic cells (DCs) function, but fundamental questions remain about how this group of cells develops in humans and how this process goes awry in disease. A thread on our new work! (1/9)
https://t.co/9hgDt3r8n1
📢Another exciting seminar on CCEC, scheduled on Friday 6thJun@3PM,UKtime with Alvaro Rada Iglesias @IBBTEC Cantabria.
Alvaro will discuss: Enhancer-Promoter contact, a key feature in gene regulation, how and why?? link2join https://t.co/V7gUW5YReJ
@ShuchiChromaBio@activemotif
🧵 NEW PAPER in @BloodJournal!
Why do IDH1 mutations almost exclusively drive myeloid #leukemia, while IDH2 mutations occur in both myeloid AND lymphoid cancers? #AML#Epigenetics
Despite sharing the same biochemical mechanism, they are NOT equivalent. Here's what we found 👇
Grateful to @JianXuLab for this perspective highlighting how oncogenes, developmental ontogeny, and cellular plasticity intersect in pediatric leukemia, alongside the JMML study by @mp_hartmann and @dblipka1. @BCD_AACR@CD_AACR https://t.co/n9cN5J4hz1
Now online: Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia https://t.co/lsPJPaJLr3
Check out our latest story https://t.co/7wLiJlYDyy! Huge thanks to @GauravA_UK and the @bloodgenes lab for driving this work forward together with us. This was a great team effort with outstanding collaborators @_ruslansoldatov, @AbdelWahablab, and @AlexBickMDPhD.
Here, in this @Cancer_Cell mini-review, we highlight recent advances in understanding oncofetal reprogramming and explore its emerging potential as a biomarker and therapeutic target in cancer research. @FGinhoux
https://t.co/Kmq40vqItQ